JP2005514414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514414A5 JP2005514414A5 JP2003557606A JP2003557606A JP2005514414A5 JP 2005514414 A5 JP2005514414 A5 JP 2005514414A5 JP 2003557606 A JP2003557606 A JP 2003557606A JP 2003557606 A JP2003557606 A JP 2003557606A JP 2005514414 A5 JP2005514414 A5 JP 2005514414A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- treating
- omalizumab
- allergic
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 20
- 208000026935 allergic disease Diseases 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000003266 anti-allergic effect Effects 0.000 claims description 14
- 229960000470 omalizumab Drugs 0.000 claims description 13
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 10
- 229960005330 pimecrolimus Drugs 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 7
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 6
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 6
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 6
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 6
- 108091000080 Phosphotransferase Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 6
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 230000002584 immunomodulator Effects 0.000 claims 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims 6
- 230000001861 immunosuppressant effect Effects 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 6
- 239000003226 mitogen Substances 0.000 claims 6
- 102000020233 phosphotransferase Human genes 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 3
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 description 9
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0200429.9A GB0200429D0 (en) | 2002-01-09 | 2002-01-09 | Organic compounds |
| PCT/EP2003/000154 WO2003057249A1 (en) | 2002-01-09 | 2003-01-09 | Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514414A JP2005514414A (ja) | 2005-05-19 |
| JP2005514414A5 true JP2005514414A5 (https=) | 2006-02-02 |
Family
ID=9928810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557606A Pending JP2005514414A (ja) | 2002-01-09 | 2003-01-09 | 抗ＩｇＥ抗体および抗アレルギー性化合物を投与することを含むアレルギー疾患についての組合せ療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050042215A1 (https=) |
| EP (1) | EP1465662A1 (https=) |
| JP (1) | JP2005514414A (https=) |
| CN (1) | CN1612751A (https=) |
| AU (1) | AU2003210153A1 (https=) |
| BR (1) | BR0306732A (https=) |
| CA (1) | CA2472151A1 (https=) |
| GB (1) | GB0200429D0 (https=) |
| WO (1) | WO2003057249A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512946A (ja) * | 2001-05-09 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 選択的免疫調節法 |
| GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| CA2539324A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
| GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP4974903B2 (ja) * | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| PL2001466T3 (pl) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
| AU2008215926B2 (en) * | 2007-02-15 | 2012-07-19 | Astrazeneca Ab | Binding members for IgE molecules |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| BR112020006339A2 (pt) * | 2017-11-07 | 2020-11-03 | Hubit Genomix, Inc. | método para prevenção primária de distúrbios alérgicos durante a infância através de imunossupressão específica da classe ige |
| US20210115155A1 (en) * | 2018-03-26 | 2021-04-22 | Novartis Ag | Methods of treating chronic spontaneous urticaria using ligelizumab |
| CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| WO2000016804A1 (en) * | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| GB0012383D0 (en) * | 2000-05-22 | 2000-07-12 | Novartis Ag | Organic compounds |
-
2002
- 2002-01-09 GB GBGB0200429.9A patent/GB0200429D0/en not_active Ceased
-
2003
- 2003-01-09 BR BR0306732-7A patent/BR0306732A/pt not_active IP Right Cessation
- 2003-01-09 EP EP03729238A patent/EP1465662A1/en not_active Withdrawn
- 2003-01-09 AU AU2003210153A patent/AU2003210153A1/en not_active Abandoned
- 2003-01-09 JP JP2003557606A patent/JP2005514414A/ja active Pending
- 2003-01-09 US US10/500,200 patent/US20050042215A1/en not_active Abandoned
- 2003-01-09 CA CA002472151A patent/CA2472151A1/en not_active Abandoned
- 2003-01-09 CN CNA03802053XA patent/CN1612751A/zh active Pending
- 2003-01-09 WO PCT/EP2003/000154 patent/WO2003057249A1/en not_active Ceased
-
2006
- 2006-06-19 US US11/455,431 patent/US20060240000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514414A5 (https=) | ||
| US9993512B2 (en) | Use of escin | |
| CN1127983C (zh) | 免疫调节、抗炎症剂 | |
| CN104010656B (zh) | 使用免疫球蛋白和c1-抑制剂的联合疗法 | |
| JPH02501573A (ja) | ＩｇＥ非関与型疾病の治療方法および治療用組成物 | |
| US20080206237A1 (en) | Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent | |
| JP2023139175A (ja) | 免疫系の変化及びアレルギー疾患の治療又は予防のための血漿免疫グロブリンと抗原特異的免疫グロブリンとの組み合わせ | |
| US20060240000A1 (en) | Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound | |
| US6187803B1 (en) | Drug preparation for oral administration | |
| JP3468515B2 (ja) | Ｔｎｆに対する抗体またはその誘導フラグメントおよびキサンチン誘導体の組み合わせ治療およびそのための組成物についての使用 | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| JPH03227921A (ja) | ケロイド治療剤 | |
| KR100756974B1 (ko) | 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트 | |
| JP6058156B2 (ja) | アトピー性皮膚炎を処置するためのピドチモドの使用 | |
| US4829068A (en) | Treatment of disorders of the gastro-intestinal tract | |
| EA019903B1 (ru) | Фармацевтические композиции на основе антагонистов кининового рецептора в2 и кортикостероидов и их применение | |
| JP4221266B2 (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤 | |
| WO2002034199A2 (en) | Medicine intended for treatment of multiple sclerosis | |
| JP2021509411A (ja) | 非ステロイド系選択的グルココルチコイド受容体アゴニスティック調節因子（ｓｅｇｒａｍ）およびその使用 | |
| Rotaru et al. | Etiopathogenic and therapeutic considerations in atopic dermatitis | |
| KR20030005042A (ko) | 면역학적 질환의 치료를 위한 배합 제제 | |
| JP2023099143A5 (https=) | ||
| Sorbera | Metelimumab | |
| JP2004510748A (ja) | プールヒト免疫グロブリン及び制酸剤の経口投与による若年性関節リウマチの処置 | |
| JP2000327571A (ja) | 抗かゆみ組成物 |